Jay Passmore
Nurse Practitioner · Chattanooga, TNNPI 1063804532
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,902 of the $12,591 with a category attached, or 86.6%. It is spread thinly across 33 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,236, 2.6 times the $1,634 reported in 2021. Among nurse practitioner clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- Johnson & Johnson$2K
- AbbVie$1K
- Novartis$977
- Lilly USA, LLC$930
- Sun Pharmaceutical Industries Inc.$893
- plus $4K from 27 others
What the payments were for
- Consulting fees$1,1259%
- Food & beverage$10,90287%
- Education$5644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 58 | $2,450 |
| Johnson & Johnson | 41 | $2,067 |
| AbbVie | 68 | $1,375 |
| Novartis | 77 | $977 |
| Lilly USA, LLC | 56 | $930 |
| Sun Pharmaceutical Industries Inc. | 40 | $893 |
| Sanofi | 16 | $830 |
| UCB, Inc. | 17 | $391 |
| Pfizer | 10 | $346 |
| Dermavant Sciences, Inc. | 16 | $318 |
| Galderma Laboratories, L.p. | 17 | $291 |
| Incyte Corporation | 19 | $282 |
| LEO Pharma Inc. | 14 | $206 |
| Amgen | 10 | $203 |
| Arcutis Biotherapeutics, Inc. | 9 | $149 |
| Boehringer Ingelheim | 5 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Mayne Pharma Commercial LLC | 5 | $93 |
| Mallinckrodt Hospital Products Inc. | 4 | $93 |
| Organon | 3 | $73 |
| Biofrontera Inc. | 3 | $56 |
| Abbott | 3 | $49 |
| VYNE Pharmaceuticals Inc. | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Convatec Inc. | 1 | $33 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Almirall LLC | 1 | $26 |
| Kerecis Limited | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Smith+Nephew | 1 | $20 |
| EPI Health, LLC | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,591 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 137 | $541,820 |
| Humira(Cf) PenAdalimumab | 42 | $468,099 |
| Cosentyx Unoready PenSecukinumab | 21 | $213,743 |
| Taltz AutoinjectorIxekizumab | 25 | $192,261 |
| OtezlaApremilast | 14 | $69,163 |
| XolairOmalizumab | 11 | $29,947 |
| Fluorouracil | 74 | $6,800 |
| Clobetasol Propionate | 93 | $4,013 |
| Ketoconazole | 195 | $2,967 |
| Triamcinolone Acetonide | 170 | $2,058 |
| Doxycycline Hyclate | 81 | $1,897 |
| Metronidazole | 27 | $1,470 |
| Clindamycin Phosphate | 24 | $531 |
| Hydrocortisone | 74 | $376 |
| Terbinafine Hcl | 12 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $203 | $69,16314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Honor HightshueChattanooga$45K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.